Table 1. Epidemiological, clinical, and laboratory features of 105 HBsAg-reactive patients coinfected with HIV.
| Demographic and epidemiological variables | n | % |
|---|---|---|
| Men | 102 | 97.1 |
| Mean age (years) | 50.4 | SD = 8.2 |
| Background MSM | 54 | 51.4 |
| Background IDU | 6 | 5.7 |
| Clinical variables | ||
| Previous ARV use | 105 | 100 |
| Previous lamivudine use | 101 | 96.0 |
| Previous tenofovir use (TDF) | 78 | 74.0 |
| Previous LAM, TDF, ENT, or IFN use | 101 | 96.0 |
| Previous entecavir use (ENT) | 4 | 3.8 |
| Previous interferon use (IFN) | 5 | 4.7 |
| History of AIDS-defining illness | 46 | 43.8 |
| Laboratory variables | ||
| HBeAg reactivity | 61 | 58.0 |
| Mean CD4+ T-cells | 4,492 | Variation: 10-1,536 SD = 211.5 cells/mm3 |
| Elevation ALT >1.5 × ULN† | 61 | 58.0 |
MSM: men who have sex with men; IDU: injection drug use; ARV: antiretroviral drug; TDF: Tenofovir; LAM: Lamivudine; ENT: Entecavir; IFN: Interferon; ALT: alanine aminotransferase; ULN: upper limit of normality